Roche Holding AG

RHHBYCH

Roche Holding AG functions as a major global healthcare enterprise, primarily concentrating its efforts within the pharmaceutical and diagnostic sectors. The company boasts an extensive international presence, with key operations located in countries such as Switzerland, Germany, the United States, Austria, the Netherlands, the United Kingdom, France, and Belgium. Its pharmaceutical division is dedicated to creating and supplying a diverse array of therapeutic remedies. These target a broad spectrum of medical fields, including oncology, neuroscience, immunology, cardiovascular and metabolic disorders, ophthalmology, and respiratory ailments. The comprehensive product line further extends to treatments for specific conditions like infectious diseases, anemia, various dermatological issues, hemophilia, inflammatory and autoimmune disorders, neurological conditions, and transplantation-related needs. Within its diagnostics segment, Roche develops and markets a wide variety of laboratory-based tests designed to identify and monitor numerous illnesses. These include, but are not limited to, cancer, diabetes, Covid-19, hepatitis, and human papillomavirus. Additionally, the company is a provider of essential diagnostic instruments and reagents. Established in 1896, Roche Holding AG maintains its corporate headquarters in Basel, Switzerland.

Founded1896IPO year2003As of2026-08-04
Market Cap
$352.00B
Enterprise Value
$374.00B
EV / LTM Revenue
5.9x
EV / NTM Revenue
5.9x
Trading multiples

Enterprise value over trailing (LTM) vs. forward (NTM) fundamentals. Click an LTM cell to chart it.

LTM
trailing
NTM
forward
Revenue
5.9x
Gross Profit
8.1x
EBITDA
18.2x
Classification
Sector
Pharma & Biotech
Sub-sector
Large-Cap & Specialty Pharmaceuticals
Listing
RHHBY
Country
CH
Historical valuation & fundamentals

EV / LTM Revenue

Annual financials & analyst forecasts

$MCY2026ECY2027E
Revenue YoY4%
Revenue$61.45B$64.13B
Gross Profit
Gross Profit Margin
EBITDA$20.07B$20.94B
EBITDA Margin32.7%32.7%
EBIT$16.51B$17.22B
Net Income$15.84B$17.09B
Free Cash Flow
FCF Margin
Short-Term Debt
Long-Term Debt
Cash & Cash Equivalents
Net Debt
Net Debt / EBITDA
Rule of 40
Figures in $M. True calendar years (Jan–Dec) built from quarterly data — income & cash-flow lines summed across the four quarters, balance sheet as of year-end. E columns are calendarized analyst consensus — gross profit, cash flow and balance-sheet lines are not estimated. Net debt = short-term debt + long-term debt − cash & cash equivalents; Rule of 40 = YoY revenue growth + FCF margin.